From: One-year treatment with mometasone furoate in chronic obstructive pulmonary disease
 | MF-DPI 800 μg QD PM (n = 308) | MF-DPI 400 μg BID (n = 308) | Placebo (n = 295) |
---|---|---|---|
Any adverse event, n (%) | 224 (73) | 228 (74) | 204 (69) |
URTI, n (%) | 82 (27) | 82 (27) | 71 (24) |
Oral candidiasis, n (%) | 34 (11) | 30 (10) | 10 (3) |
Pharyngitis, n (%) | 26 (8) | 28 (9) | 24 (8) |
Bruise/bruising*, n (%) | 46 (15) | 45 (14) | 33 (11) |
New forearm bruising†, n (%) | 27 (10) | 27 (10) | 21 (7) |
Back pain, n (%) | 23 (7) | 15 (5) | 10 (3) |
COPD aggravated, n (%) | 11 (4) | 12 (4) | 14 (5) |
Pneumonia, n (%) | 12 (4) | 13 (4) | 6 (2) |